Breast biopsy - Medium 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

To identify cancerous, precancerous, or non-cancerous changes

₹350₹1,000

65% OFF

Breast Biopsy - Medium 1-3 cm: Comprehensive Medical Test Guide

Why is it done?
- A breast biopsy is a procedure that removes a tissue sample from the breast for microscopic examination to diagnose whether an abnormality is benign (non-cancerous) or malignant (cancerous).
- Primary Indications:
- Abnormal mammography findings requiring confirmation
- Palpable breast lumps or masses (1-3 cm in size)
- Ultrasound-detected solid nodules requiring tissue diagnosis
- MRI-identified lesions needing pathological confirmation
- Suspicious architectural distortion or calcifications
- Follow-up of previously biopsied lesions with indeterminate results
- Typical Timing:
- Performed as soon as possible after abnormality detection, typically within 1-2 weeks of imaging findings or clinical evaluation
- Medium-sized lesions (1-3 cm) are ideal for percutaneous biopsy techniques
Normal Range
- Normal Results (Benign Findings):
- Benign breast tissue (normal adipose and fibroglandular tissue)
- Fibroadenoma (benign tumor)
- Fibrocystic changes
- Lipoma (fatty benign lesion)
- Papilloma
- Abnormal Results (Malignant or High-Risk Findings):
- Invasive Ductal Carcinoma (IDC)
- Invasive Lobular Carcinoma (ILC)
- Ductal Carcinoma In Situ (DCIS)
- Atypical Ductal Hyperplasia (ADH)
- Atypical Lobular Hyperplasia (ALH)
- BI-RADS Classification System:
- BI-RADS 2: Benign finding (typically no biopsy needed)
- BI-RADS 3: Probably benign (short-term follow-up recommended)
- BI-RADS 4: Suspicious abnormality (biopsy recommended)
- BI-RADS 5: Malignant (biopsy strongly recommended)
Interpretation
- Benign Diagnoses:
- Indicates no malignancy present; lesion does not require cancer treatment
- Routine imaging follow-up may still be recommended for surveillance
- High-Risk/Precancerous Lesions (ADH, ALH):
- Indicate increased risk for future breast cancer development
- Requires close clinical surveillance, possibly enhanced imaging
- Consider preventive therapy (tamoxifen, aromatase inhibitors) discussion with oncologist
- Carcinoma In Situ (DCIS):
- Pre-malignant condition; cancer cells present but have not invaded surrounding tissue
- Requires treatment (usually surgery, possible radiation therapy)
- Invasive Carcinoma (IDC, ILC):
- Confirms breast cancer diagnosis; cells have invaded surrounding normal breast tissue
- Requires comprehensive staging (tumor grading, hormone receptor status, HER2 testing)
- Treatment planning (surgery, chemotherapy, radiation, hormonal therapy)
- Factors Affecting Interpretation:
- Specimen adequacy - sufficient tissue for accurate diagnosis
- Sampling error - lesion may not be completely sampled
- Concordance with imaging findings - correlation between biopsy results and radiologic appearance
- Pathologist expertise in breast tissue analysis
Associated Organs
- Primary Organ System:
- Breast tissue (mammary gland) - including ductal and lobular epithelium, adipose tissue, and supporting connective tissue
- Associated Medical Conditions:
- Breast cancer (ductal and lobular carcinomas)
- Inflammatory breast cancer
- Phyllodes tumors
- Lymphoma of the breast
- Fibrocystic disease
- Fat necrosis
- Breast abscess and infection
- Potential Complications with Abnormal Results:
- Metastatic disease - spread to lymph nodes, bones, liver, lungs, or brain
- Regional lymph node involvement requiring axillary evaluation
- Chest wall invasion in advanced disease
- Increased mortality risk if untreated or delayed treatment
- Psychological impact and quality of life considerations
Follow-up Tests
- If Benign Result:
- Routine mammographic surveillance - typically annual or per screening guidelines
- Ultrasound follow-up if lesion has cystic component
- If High-Risk Lesions (ADH, ALH) Diagnosed:
- Enhanced breast imaging (supplemental ultrasound, MRI) - every 6-12 months
- Genetic testing (BRCA1/BRCA2 mutations) if family history present
- Oncology or breast surgery consultation for risk stratification
- Consideration of preventive therapy (tamoxifen or aromatase inhibitors)
- If DCIS Diagnosed:
- Breast surgical consultation for definitive treatment planning
- Wide local excision or mastectomy
- Radiation therapy (typically after breast-conserving surgery)
- Hormone receptor testing (ER/PR/HER2)
- If Invasive Carcinoma Diagnosed:
- Comprehensive tumor staging (TNM classification)
- Hormone receptor status (Estrogen and Progesterone receptors)
- HER2 protein expression testing (immunohistochemistry and FISH)
- Ki-67 proliferation index assessment
- Sentinel lymph node biopsy for nodal staging
- Staging imaging: Chest CT, bone scan, or PET-CT for metastatic disease screening
- Oncology consultation for treatment planning (surgery, chemotherapy, radiation, endocrine therapy)
- Genetic counseling if high-risk features present
- Monitoring Frequency:
- Benign lesions: Annual mammography
- High-risk lesions: Every 6 months enhanced imaging for first 2 years, then annual
- Cancer diagnosis: Clinical follow-up every 3-4 months first 2 years, then as per oncology protocol
Fasting Required?
- Fasting Required: No
- Pre-Procedure Instructions:
- No dietary restrictions - normal food and beverage intake permitted
- Continue current medications unless specifically instructed otherwise
- Inform radiologist of blood thinner use (warfarin, dabigatran, apixaban) - may require temporary discontinuation
- Aspirin and NSAID use - typically can continue but discuss with biopsy team
- Clothing and Preparation:
- Wear comfortable, loose-fitting clothing
- Avoid metal accessories or medical alert devices in biopsy area
- Avoid deodorant, perfume, or powder on breast and underarm area
- Arrive 15 minutes early for check-in and consent forms
- Medications to Avoid/Consider:
- Anticoagulants - may need to discontinue 3-5 days prior (consult with prescribing physician)
- Herbal supplements (ginkgo, ginger, garlic) - may increase bleeding risk; discontinue 1 week prior if possible
- Local anesthetic for the procedure typically used - no need for general anesthesia
- Post-Procedure Care:
- Ice pack application for first 24 hours - reduces swelling and discomfort
- Support bra recommended for several days
- Avoid strenuous activity and heavy lifting for 3-5 days
- Pain management - acetaminophen or prescribed analgesics for discomfort
- Monitor biopsy site for excessive bleeding, bruising, or signs of infection
- Results typically available within 7-10 business days

How our test process works!